Lilly Completes $8 Billion Acquisition of Loxo Oncology to Expand Precision Oncology Portfolio

February 16, 2019 /BioonBIOON/ -- U.S. pharmaceutical giant Eli Lilly recently announced the completion of its acquisition of Loxo Oncology. This acquisition will enhance the pipeline of highly selective potential therapies for patients with genetically defined cancers.Eli LillyTumorThe academic portfolio has expanded into the field of precision medicine.

In early January this year, Eli Lilly and Company reached a final agreement with Loxo Oncology to acquire the latter for $235 per share in cash, totaling approximately $8 billion. This acquisition also marksEli LillyThe largest in a series of transactions undertaken to expand its oncology portfolio.

Eli LillyAnne White, President of Oncology, stated, “We are pleased to announce the completion of the acquisition of Loxo Oncology, which will expand our”Tumor“...expanding our product portfolio into the field of precision medicine, specifically targeting cancers caused by specific genetic abnormalities. We look forward to collaborating with the Loxo Oncology team to continue rapidly advancing this groundbreaking scientific innovation and improving the lives of cancer patients.”

Josh Bilenker, CEO of Loxo Oncology, stated, “The Loxo Oncology team has remained steadfast and united around our shared mission of delivering highly selective medicines to patients with genetically defined cancers. With the completion of the acquisition, we look forward to realizing the full potential of our pipeline, supported by our teams in Connecticut, Colorado, and California.”

Acquisition of Loxo Oncology, forEli LillyBrings a portfolio of promising investigational drugs, including:

——LOXO-292: This is a first-in-class oral RET inhibitor, which has been approvedFDAGranted Breakthrough Therapy Designation for three indications, with anticipated market approval in 2020. LOXO-292 targets cancers with alterations in the Rearranged during Transfection (RET) kinase, including RET fusions and mutations occurring across various tumor types.Tumorin, including certain lung cancers and thyroid cancers, as well as other cancer subsets.

——LOXO-305, an oral BTK inhibitor currently in Phase I/II clinical development. LOXO-305 targets cancers with Bruton's tyrosine kinase (BTK) mutations, aiming to address resistance to currently available BTK inhibitors. BTK is a validated molecular target widely expressed in various B cellsLeukemiaand in lymphoma.

In November 2017, Loxo Oncology andBayerEstablished a global collaboration on the development and commercialization of two TRK inhibitors, Vitrakvi (larotrectinib) and LOXO-195. The Bayer/Loxo Oncology agreement stipulates that, in the event of a change in control of Loxo Oncology, Bayer may elect to convert the co-exclusive license for the United States and Puerto Rico into an exclusive license.

Bayer has exercised its option under the Bayer/Loxo Oncology Agreement to convert its co-exclusive license in the United States and Puerto Rico into an exclusive license, pending antitrust approval under the Hart-Scott-Rodino Antitrust Improvements Act. Upon the effectiveness of the new exclusive license agreement,Eli LillyWill receive royalties from Bayer for the sales of Vitrakvi and Loxo-195 in the U.S. and international markets. (Bioon.com)

Original Source:Lilly Completes Acquisition of Loxo Oncology